Close Menu

John Lechleiter has been named the new CEO of Eli Lilly, reports the Wall Street Journal, and Derek Lowe thinks that's unusual (but still cool) because Lechleiter's a researcher who worked his way up from the bench to management. Lowe ponders why that doesn't happen more often in pharma. One reason is that a lot of scientists don't want to be managers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.